TABLE 4.
Autoimmune serology.
| Autoantibodies | All patients (n = 107) | CTD-ILD (n = 63) | IPAF (n = 44) | p-value |
|---|---|---|---|---|
| ANA, n (%) | 71 (66.36) | 43 (68.25) | 28 (63.64) | 0.330 |
| RF, n (%) | 22 (20.56) | 11 (17.46) | 11 (25.00) | 0.466 |
| ACPA, n (%) | 10 (9.35) | 5 (7.94) | 5 (11.36) | 0.738 |
| Anti-RNA-polymerase, n (%) | 0 | 0 | 0 | – |
| Anti-centromere, n (%) | 1 (0.93) | 1 (1.59) | 0 | – |
| Anti-PCNA, n (%) | 2 (1.87) | 1 (1.59) | 1 (2.27) | 1.000 |
| Anti-Ku, n (%) | 0 | 0 | 0 | 0 |
| Anti-P-ribosomal, n (%) | 0 | 0 | 0 | 0 |
| Anti-cytoplasmatic, n (%) | 27 (25.23) | 17 (26.98) | 10 (22.73) | 0.658 |
| Anti-cytoskeleton, n (%) | 0 | 0 | 0 | 0 |
| Anti-chromatin, n (%) | 32 (29.90) | 19 (30.16) | 13 (29.55) | 1.000 |
| Anti-Smith, n (%) | 4 (3.73) | 2 (3.17) | 2 (4.55) | 1.000 |
| Anti-myeloperoxidase, n (%) | 2 (1.87) | 2 (3.17) | 0 | – |
| Anti-proteinase-3, n (%) | 1 (0.93) | 1 (1.59) | 0 | – |
| Anti-Jo-1, n (%) | 3 (2.80) | 2 (3.17) | 1 (2.27) | 1.000 |
| Anti-SS-A, n (%) | 18 (16.82) | 12 (19.05) | 6 (13.64) | 0.602 |
| Anti-SS-B, n (%) | 5 (4.67) | 3 (4.76) | 2 (4.55) | 1.000 |
| Anti-SCL-70, n (%) | 17 (15.88) | 17 (26.98) | 0 | – |
| Anti-RNP, n (%) | 10 (9.34) | 8 (12.70) | 2 (4.55) | 0.192 |
| ANCA, n (%) | 8 (7.48) | 4 (6.35) | 4 (9.09) | 0.714 |
CTD-ILD, connective tissue disease-associated interstitial lung disease; IPAF, interstitial pneumonia with autoimmune features; ANA, anti-nuclear antibodies; RF, rheumatoid factor; ACPA, anti-cyclic citrullinated peptide antibodies; APCNA, anti-proliferating cell nuclear antigen; ANCA, anti-neutrophil cytoplasmic antibodies.